Mortality and morbidity in transsexual subjects treated with cross‐sex hormones

@article{vanKesteren1997MortalityAM,
  title={Mortality and morbidity in transsexual subjects treated with cross‐sex hormones},
  author={Paul J M van Kesteren and Henk Asscheman and J. A. J. Megens and Louis J Gooren},
  journal={Clinical Endocrinology},
  year={1997},
  volume={47}
}
The optimum steroid hormone treatment regimes for transsexual subjects has not yet been established. We have investigated the mortality and morbidity figures in a large group of transsexual subjects receiving cross‐sex hormone treatment. 
Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta‐analyses
TLDR
The available evidence on the cardiovascular effects of cross‐sex steroid use in transsexuals is summarized to summarized. Expand
Cross‐sex hormone therapy in Australia: the prescription patterns of clinicians experienced in adult transgender healthcare
Despite increasing demand for transgender healthcare, guidelines for cross‐sex hormone therapy are based on low‐level evidence only. As most data are based on international expert opinions,Expand
Hormone management of trans women
In the previous issue, the authors introduced some principles underlying the medical management of transgender people, before focusing on trans men. In this article they look at the hormonalExpand
Endocrine Treatment of Transsexual Male-to-Female Persons
TLDR
A reduction of endogenous hormone levels by antiandrogens and their replacement with those of the reassigned sex (estrogens) are needed for gender dysphoric male-to-female adults. Expand
Long-term cross-sex hormone treatment is safe in transsexual subjects.
TLDR
It is suggested that mortality is increased among transsexuals although due to causes unrelated to cross sex replacement therapy, which will benefit the care and treatment of these subjects. Expand
Gender‐affirming hormone therapy and the risk of sex hormone‐dependent tumours in transgender individuals—A systematic review
TLDR
Whether tumour risk in transgender individuals differs from the general population, to guide clinical screening recommendations, is sought. Expand
Hormone management of trans men
In this article the authors describe how hormonal treatments are used in trans men undergoing transition. The hormone regimens are explained and the vital role of primary care in managing ongoingExpand
Hormone Treatment of the Adult Transsexual Patient
  • L. Gooren
  • Medicine
  • Hormone Research in Paediatrics
  • 2005
TLDR
The goal of treatment in female-to-male transsexuals is to induce virilization, including a male pattern of sexual hair, a male voice and male physical contours, and to stop menses. Expand
Effects of antiandrogens on prolactin levels among transgender women on estrogen therapy: A systematic review
Gender-affirming hormone therapy for transgender women includes estrogen and antiandrogens (cyproterone acetate, spironolactone, or gonadotropin-releasing hormone agonists). Both estrogen and antia...
Effect of gender‐affirming hormone use on coagulation profiles in transmen and transwomen
TLDR
The transgender population that uses gender‐affirming hormone therapy (GAHT) is rapidly growing and the effects of GAHT on coagulation parameters associated with venous thromboembolism risk are examined. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 32 REFERENCES
Mortality and morbidity in transsexual patients with cross-gender hormone treatment.
TLDR
The dilemma of prescribing cross gender hormones in view of the needs of these patients is not resolved, and follow up of this relatively young population to disclose long-term side effects and to elucidate the association of sex steroids with coronary heart disease is required. Expand
Ischemic cerebrovascular disease and hormone therapy for infertility and transsexualism
TLDR
Two patients who experienced ischemic cerebrovascular symptoms in unusual clinical settings of hormone therapy are reported to highlight an emerging risk factor for stroke in the young. Expand
Physical and hormonal evaluation of transsexual patients: A longitudinal study
TLDR
Based on the data generated by this study, it is recommended as hormonal therapy 0.1–0.5 mg/day of ethinyl estradiol or 7.5–10 mg/ day of conjugated estrogen for male-to-female transsexuals, and intramuscular testosterone cypionate, 200 mg every 2 weeks, for female- to-male transsexuals. Expand
An androgen‐associated hepatic adenoma in a trans‐sexual
TLDR
There appears to be an association between various steroid preparations and hepatic neoplasia and reports of such cases with all relevant data will allow a balanced assessment of the problem to be made. Expand
Sex reassignment surgery: A study of 141 dutch transsexuals
TLDR
It is concluded that there is no reason to doubt the therapeutic effect of sex reassignment surgery and that more attention ought to be paid to psychosocial guidance in addition to medical guidance. Expand
Exogenous estrogen effect on lipid /lipoprotein cholesterol in transsexual males
TLDR
It is concluded that exogenous estrogens administered to transsexual males results in a female pattern of lipid/lipoprotein cholesterol and SHBG concentration, and the decreased total cholesterol/HDL ratio may imply a lower atherogenic potential and a lessened cardiovascular risk in males who take estrogens. Expand
PROLACTIN LEVELS AND PITUITARY ENLARGEMENT IN HORMONE‐TREATED MALE‐TO‐FEMALE TRANSSEXUALS
TLDR
The data suggest that the lowest possible oestrogen dose and lifelong follow-up of hormone‐treated male‐to‐female transsexuals is essential. Expand
Cerebrovascular occlusion in a transsexual man taking mestranol.
TLDR
A case in which a previously healthy man who was using an oral contraceptive drug developed middle cerebral artery occlusion appears to have been related to estrogen administration, and the occurrence of persistent severe headaches in patients using estrogenic hormones may be a clue to impending cerebrovascular occlusions. Expand
LIVER DAMAGE FROM LONG-TERM METHYLTESTOSTERONE
TLDR
Of the androgens, only 17alpha-alkylated steroids seem to be implicated in the development of cholestatic jaundice, peliosis hepatis, and liver tumours. Expand
Effects of estrogens only on the prostates of aging men.
TLDR
Prostates were small after long-term estrogens only, and biopsies showed PSA and PAP in the specimens suggested that their production does not depend on testicular androgens alone. Expand
...
1
2
3
4
...